LCT collaborates to develop novel neurological treatments
Living Cell Technologies collaborates to develop novel neurological treatments
Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT’s lead product NTCELL®.
Directed by Professor Richard Faull, ONZM MBChB PhD DSc FRSNZ, University of Auckland Distinguished Professor, the CBR has a specialised interest in neurodegenerative diseases such as Parkinson’s, Huntington’s, motor neurone and Alzheimer’s diseases.
LCT has the expertise to identify and commercialise treatments and products from CBR research. Its therapeutic treatment NTCELL is currently in a Phase I/IIa clinical study targeting Parkinson’s patients who have failed current symptomatic therapy.
Professor Richard Faull said, “The results of LCT’s research studies are impressive and provide strong evidence that NTCELL has the potential to provide significant improvement in patients with Parkinson’s disease. We believe this collaboration can help realise the potential of cell therapy for neurodegenerative diseases.”
Dr Ken Taylor, LCT chief executive said, “The collaboration is in line with our focus to develop and market NTCELL therapy for Parkinson’s patients failing current therapy while also investigating the potential of our patented cell therapy for other neurodegenerative disorders.”
– Ends –
For further information: www.lctglobal.com